Increase in BMD | Prolia Treatment | Amgen

PROLIA® TREATMENT IS ASSOCIATED WITH CONTINUOUS BMD INCREASE OVER 10 YEARS1,2

After 10 years of Prolia® treatment, improved BMD at the hip is associated with a lower incidence of non-vertebral fracture.1,3
In the FREEDOM extension, Prolia® continuously increased BMD at key skeletal sites over 10 years, including total hip, lumbar spine and femoral neck.1
Percentage changes from FREEDOM and extension baselines in BMD for the lumbar spine, total hip and one-third distal radius. Final numbers listed after 10 years represent BMD percentage change while on Prolia® treatment. Data are least-squares means (95% confidence intervals).1
*p<0.05 compared with FREEDOM baseline.
p<0.05 compared with FREEDOM and extension baselines.
ǂp<0.05 compared with extension baseline.
Prolia® leads to rapid and profound decreases in bone turnover markers as early as 1 month. Sustained reductions in sCTx-1 and P1NP were observed over 10 years.1
Prolia® continuously increases hip BMD, whereas a therapeutic plateau is observed after 3-4 years of bisphosphonate therapy1,2

READ MORE

AMG_BrandAdvance_Hip BMD
Data are derived from long-term follow-up studies of the FLEX trial (alendronate 5–10 mg per day), the HORIZON trial (zoledronic acid 5 mg per year) and the FREEDOM trial (Prolia® 60 mg every 6 months). Data are least-squares means (95% confidence intervals).2
Data are taken from independent studies and not head-to-head comparisons. Caution must be taken when interpreting these data.

References:
BMD: bone mineral density; P1NP: procollagen type 1 N-terminal propeptide; sCTx-1: serum C-terminal telopeptide of type 1 collagen.
  1. Bone HG, et al. Lancet Endocrinol Diabetes. 2017;5:513–23.
  2. Reid IR. Nat Rev Endocrinol. 2015;11:418–28.
  3. Ferrari S, et al. Osteoporos Int. 2016;27(Suppl 1): OC17.

SMPC

The information contained in this site is for healthcare professionals only

I am a patient
I am a member of the public